Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-03-09
Based on 406 first isolates · MED-B · Cystitis (lower UTI) · 2024-03-10 → 2025-03-09
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 81 % (77 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
84 %
79 %
n = 28
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
81 %
75 %
n = 28
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
79 %
n = 28
ceftriaxone CRO
trend · Escherichia coli
78 %
71 %
n = 28
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
75 %
n = 28
ciprofloxacin CIP
trend · Escherichia coli
75 %
75 %
n = 28
73 %
68 %
n = 28
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
68 %
n = 28
52 %
50 %
n = 28
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
14 %
21 %
n = 28
4 %
0 %
n = 28
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
7 %
n = 28

Most likely organisms for this profile

Escherichia coli
55 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
4 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.